These two reliable and high-yielding dividend payers from the healthcare sector should be on your buy list today.

An artificial intelligence-based image analysis model has more accurately predicted cancer biomarkers and outcomes compared with conventional methods.

Zusduri is the first non-surgical therapy to be approved for NMIBC, setting a new standard for the indication.

MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces it has received positive and ...

Thousands of Medicare recipients will face higher costs for expensive cancer drugs following passage of two provisions in the One Big Beautiful Bill Act, signed by President Donald Trump in July, The ...